JuliaBGarcia-DiazMDMSc

Infectious Disease • New Orleans, LA

Medical Director at Thermo Fisher

Join to view full profile

Dr. Garcia-Diaz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Garcia-Diaz's full profile

Already have an account?

Office
1514 Jefferson Hwy
New Orleans, LA 70121
Phone+1 504-842-4000

Summary

Dr. Julia Garcia-Diaz is an infectious disease specialist in New Orleans, LA and is affiliated with Ochsner Medical Center. She received her medical degree from Louisiana State University School of Medicine in New Orleans and has been in practice 24 years. She also speaks multiple languages, including Spanish. She is experienced in hiv/aids, wound management, transplant infectious disease, and fungal infections, and solid organ transplantation.

Education & Training

Ochsner Clinic FoundationFellowship, Infectious Disease, 1996 - 1998
Ochsner Clinic FoundationResidency, Internal Medicine, 1993 - 1996
Louisiana State University School of Medicine in New OrleansClass of 1993

Certifications & Licensure

LA State Medical License 1994 - 2025

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Study of Nitazoxanide in the Treatment of Clostridium Difficile-associated Disease Start of enrollment: 2006 Dec 01
Terminated
Phase 3
SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI) Start of enrollment: 2015 May 01
Completed
Phase 2
Investigational Microbiota Restoration Therapeutic for Hepatic Encephalopathy Start of enrollment: 2021 Mar 01
Terminated
Phase 2
Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19) Start of enrollment: 2020 Apr 11
Completed
Phase 2, Phase 3
Join now to see all

Publications & Presentations

PubMed

3 citations
A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes ...
Pablo C Okhuysen, Mayur S Ramesh, Thomas Louie, Nino Kiknadze, Julian Torre-Cisneros
Clinical Infectious Diseases. 2024-06-14
14 citations
Clinical Outcomes and Bacterial Characteristics of Carbapenem-resistant Acinetobacter baumannii Among Patients From Different Global Regions.
Minggui Wang, Lizhao Ge, Liang Chen, Lauren Komarow, Blake Hanson
Clinical Infectious Diseases. 2024-02-17
Whole-genome sequencing of carbapenem-resistant Enterobacterales isolates in southeast Louisiana reveals persistent genetic clusters spanning multiple locations.
Rebecca Rose, Amy Feehan, Benjamin N Lain, Deborah Ashcraft, David J Nolan
Journal of Infection and Public Health. 2023-12-01

Lectures

Seroprevalence of SARS-CoV-2 and Infection Fatality Ratio, Orleans and Jefferson Parishes, Louisiana, USA, May 2020
American Academy of Physician Assistants, New Orleans, Louisiana - 10/17/2012

Authored Content

Seroprevalence of SARS-CoV-2 and Infection Fatality Ratio, Orleans and Jefferson Parishes, Louisiana, USA, May 2020July 2020

Press Mentions

New Orleans Will Require Proof of Vaccination or a Negative Covid-19 Test to Enter Certain Indoor VenuesAugust 13th, 2021
Officials Split on Masking up Children in Schools as Pediatric Hospitals Fill up with Covid-19 PatientsAugust 7th, 2021
What Changes the Unvaccinated Minds? FearAugust 7th, 2021
Join now to see all

Other Languages

Spanish